viernes, 31 de enero de 2020

As Biogen gets squishy on timing for aducanumab filing, the clock is ticking

As Biogen gets squishy on timing for aducanumab filing, the clock is ticking

Daily Recap

STAT Plus: As Biogen gets squishy on timing for an aducanumab filing, the clock is ticking

By ADAM FEUERSTEIN


RUBY WALLAU FOR STAT
Baird analyst Brian Skorney says Biogen deserves criticism for its evasiveness on the issue of when it will submit its Alzheimer's drug to the FDA.

No hay comentarios:

Publicar un comentario